Obesity is a significant and growing public health concern in the G7 countries. The body of evidence highlighting the medical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, approved drugs are scarce compared with other chronic metabolic diseases, especially in Europe and Japan. However, the development pipeline is strengthening with novel agents that promise to address some of the limitations of current treatments. There is a huge market opportunity for antiobesity drugs that elicit greater and sustained weight loss and are safe, well tolerated, and affordable. However, given the prevalence of obesity, even if such agents are developed and approved, payers will likely need to restrict their access to limit the strain on finite healthcare budgets.
Questions answered:
CONTENT HIGHLIGHTS
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold. Additionally, Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.